Nutrition support and dietary interventions for patients with lung cancer: current insights

Nicole Kiss1,2

1Nutrition and Speech Pathology Department, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; 2Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia

Abstract: Malnutrition and weight loss are prevalent in patients with lung cancer. The impact of malnutrition on patients with cancer, and specifically in patients with lung cancer, has been demonstrated in a large number of studies. Malnutrition has been shown to negatively affect treatment completion, survival, quality of life, physical function, and health care costs. Emerging evidence is providing some insight into which lung cancer patients are at higher nutritional risk. In lung cancer patients treated with radiotherapy, stage III or more disease, treatment with concurrent chemotherapy and the extent of radiotherapy delivered to the esophagus appear to confer a higher risk of weight loss during and post-treatment. Studies investigating nutrition interventions for lung cancer patients have examined intensive dietary counseling, supplementation with fish oils, and interdisciplinary models of nutrition and exercise interventions and show promise for improved outcomes from these interventions. However, further research utilizing these interventions in large clinical trials is required to definitively establish effective interventions in this patient group.

Keywords: lung cancer, nutrition, malnutrition

Introduction

Lung cancer is the most common cancer worldwide with an estimated global incidence in 2012 of 1.8 million new cases, representing 12.9% of all new cancers.1 Treatment for lung cancer may consist of surgery, chemotherapy or radiotherapy, or any combination of these modalities. The treatment modality or combination depends on the prognostic indicators of performance status, weight loss, and stage of disease. However, other factors such as age and medical comorbidities are also taken into consideration.2,3 This review will discuss nutrition impact symptoms associated with lung cancer and its treatment, factors associated with malnutrition in lung cancer and the impact on treatment and patient outcomes, as well as review nutrition interventions used with lung cancer patients.

Symptoms that impact on nutrition

A systematic review of symptoms in adults with lung cancer found that fatigue, pain, loss of appetite, coughing, and insomnia were the most common symptoms patients presented with at diagnosis.4 In contrast, the most common symptoms experienced during chemotherapy treatment were nausea, vomiting, and hair loss, and during radiotherapy treatment were dysphagia and sore throat.4 Clinical practice guidelines for the prevention, diagnosis, and management of lung cancer patients report that anorexia, fatigue, and esophagitis are the acute toxicities associated...
with thoracic radiotherapy. An acute toxicity scoring tool developed for use in patients being treated with radiotherapy for lung cancer includes dysphagia, nausea, vomiting, skin reactions, and fatigue as the side effects that should be assessed and monitored during treatment. Patients with lung cancer have been reported to experience more symptoms than patients with other cancer diagnoses, with the type and number of symptoms varying over the course of the illness trajectory. A recent cross-sectional study of 450 patients with advanced stage non-small cell lung cancer (NSCLC) found 100% of patients experienced fatigue and 97% experienced loss of appetite.

Nutrition impact symptoms are symptoms which affect the ability to achieve adequate nutritional intake and increase the risk of developing malnutrition. Segura et al, found in their malnutrition prevalence study that the presence of two nutrition impact symptoms were associated with difficulties in food intake. A number of the symptoms and treatment toxicities reported to be experienced by patients with lung cancer include nutrition impact symptoms, specifically loss of appetite, nausea, vomiting, fatigue, dysphagia, and esophagitis, placing lung cancer patients at increased risk of malnutrition.

**Prevalence of malnutrition in lung cancer**

Oncology patients are one of the groups with the highest prevalence of malnutrition. In a cross-sectional survey of 3,122 adult patients in acute care wards, patients admitted to oncology wards were 1.7 times more likely to be malnourished than other participants. Malnutrition rates in patients with lung cancer are particularly high (Table 1). In a prospective longitudinal study of the prevalence of malnutrition in patients presenting to an Australian oncology clinic prior to chemotherapy or radiotherapy treatment, 69% of patients with lung cancer were malnourished, higher than patients with colorectal or head and neck cancer, 57% and 45% respectively. Several other studies have confirmed high rates of malnutrition or significant weight loss in patients with lung cancer. Hébuterne et al, found an overall rate of 45% malnutrition in patients with lung cancer. In the same study, a sub-analysis found 73% of lung cancer patients with metastatic disease were malnourished compared to 5% of those with localized disease. Using the patient generated subjective global assessment, a nutrition assessment tool, Segura et al, found that 56% of lung cancer patients with advanced stage disease had a score greater than nine, indicating a critical need for nutrition intervention. In a group of oncology patients presenting to European outpatient clinics the median weight loss among lung cancer patients was 6.5%, with 34.5% reporting significant weight loss of more than 10%. A prospective study designed to evaluate the nutritional status of 207 patients referred to an outpatient radiotherapy department demonstrated that 33% of lung cancer patients were malnourished prior to starting radiotherapy, increasing to 50% at the end of treatment. More recent studies in lung cancer patients receiving radiotherapy have found between 22% to 31% of patients have 5% or more weight loss within 90 days from the start of radiotherapy, with the median weight loss among these patients between 8% to 9%.

**Table 1** Malnutrition point prevalence studies in oncology patients reporting malnutrition rates in lung cancer subgroups

<table>
<thead>
<tr>
<th>Citation</th>
<th>Population</th>
<th>Setting</th>
<th>Malnutrition assessment method</th>
<th>Prevalence in lung patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mariani et al&lt;sup&gt;14&lt;/sup&gt;</td>
<td>Adult cancer outpatients at diagnosis or in various stages of treatment or follow-up, N=1,556 (n=229 (%) lung)</td>
<td>Outpatient cancer patients of 17 hospitals, universities or scientific institutions in Italy</td>
<td>Weight loss &gt;10% of usual body weight</td>
<td>34.5%</td>
</tr>
<tr>
<td>Hébuterne et al&lt;sup&gt;13&lt;/sup&gt;</td>
<td>Adult cancer inpatients, N=1,903 (n=247 (%) lung)</td>
<td>Inpatient wards of 154 public or private hospitals in France</td>
<td>BMi ≤18.5 kg/m² (for aged 18–74) or BMi =21 kg/m² (for patients aged over 75) and/or ≤10% loss of weight from beginning of disease</td>
<td>45%</td>
</tr>
<tr>
<td>Segura et al&lt;sup&gt;9&lt;/sup&gt;</td>
<td>Adult patients with advanced cancer at diagnosis or in various stages of treatment or follow-up, N=781 (n=172 (%) lung)</td>
<td>Inpatient, outpatient or home-based care patients within the Spanish National Health System</td>
<td>Patient generated subjective global assessment (PG-SGA) score &gt;9</td>
<td>56.4%</td>
</tr>
<tr>
<td>Read et al&lt;sup&gt;12&lt;/sup&gt;</td>
<td>Adult cancer patients at first presentation, prior to chemotherapy, N=141 (n=32 (%) lung)</td>
<td>Outpatient oncology clinic in two hospitals in Sydney (Australia)</td>
<td>PG-SGA category B or C</td>
<td>69%</td>
</tr>
</tbody>
</table>

**Abbreviations:** BMi, body mass index; PG-SGA, patient-generated subjective global assessment.
Importantly, approximately half of these patients reached this degree of weight loss during the post-treatment period, between 3 to 6 weeks following completion of radiotherapy, highlighting the post-treatment period as an important time to be monitoring nutrition. These studies demonstrate that malnutrition is prevalent across the disease and treatment trajectory of patients with lung cancer.

Factors associated with weight loss

In clinical practice it is useful to understand any factors present at diagnosis or during treatment that are associated with a higher risk of weight loss or developing malnutrition. This allows clinicians to ensure patients with a high risk diagnosis or a high risk treatment are identified and provided with appropriate support. In patients with head and neck cancer these factors are relatively well-known. Evidence based practice guidelines for the nutritional management of adults with head and neck cancer recommend that patients with T4 or hypopharyngeal tumors undergoing concurrent chemoradiotherapy should be considered for prophylactic placement of a percutaneous endoscopic gastrostomy tube due to the risk of weight loss and malnutrition associated with these diagnoses and treatment. The literature also suggests that all T3 and T4 head and neck tumors, and pre-treatment weight loss are associated with weight loss, and the evidence for these factors is less consistent across studies. Factors associated with weight loss and malnutrition in patients with lung cancer are just beginning to become established.

A number of studies have investigated clinical and radiotherapy dosimetric factors associated with the development of acute or late radiation-induced esophagitis in lung cancer patients. A systematic review of dose-volume parameters predictive of esophagitis in patients receiving thoracic radiotherapy found the parameters that were most consistently and strongly associated with development of esophagitis were mean esophageal dose, and the volume of the esophagus receiving a dose of 20 Gy, 30 Gy, 40 Gy, 50 Gy, and 60 Gy. A more recent systematic review and meta-analysis investigated factors predictive of clinically significant radiation-induced esophagitis in 1,082 patients from 15 studies conducted in Europe, North America, Asia, and Australia. It was identified that, while on univariate analysis several factors are predictive of radiation-induced esophagitis including disease stage, N stage, poor performance status, and type of concurrent chemotherapy, on multivariate analysis the volume of the esophagus receiving 60 Gy alone emerged as the best predictor.

Two recent studies have investigated factors associated with clinically significant weight loss in lung cancer patients receiving radiotherapy. In a retrospective cohort of 96 lung cancer patients treated with radiotherapy with or without concurrent chemotherapy 31% (n=30) of patients had clinically significant weight loss of 5% or greater within the 90 days from commencement of radiotherapy. The factors determined to be associated with ≥5% weight loss were treatment with concurrent chemotherapy for both small cell lung cancer (SCLC) and NSCLC, and late stage disease in NSCLC only. A second study of 50 NSCLC patients treated with concurrent chemo-radiotherapy investigated radiotherapy dosimetric factors associated with ≥5% weight loss. Similar to the literature reporting associations between dosimetric factors and esophagitis, an association was found between clinically significant weight loss and the maximum dose to the esophagus, and the absolute esophageal length receiving doses of 40 Gy, 50 Gy, and 60 Gy. These studies have provided new insight into the lung cancer patients who are at higher risk of nutritional decline during radiotherapy treatment (Table 2).

Impact of weight loss and malnutrition

It is well established that malnutrition and weight loss have significant negative consequences on both patient centered and treatment outcomes. Multiple international evidence-based guidelines contain statements regarding the negative impact of malnutrition on quality of life (QoL), functional status, survival, hospital length of stay, and health care costs. There are relatively few studies that have investigated the impact of malnutrition specifically in patients with lung cancer, however, many studies have been undertaken in mixed cancer populations and therefore have direct relevance to lung cancer patients.

| Table 2 Factors associated with higher nutritional risk in lung cancer patients receiving radiotherapy |
|-------------------------------------------------|-------------------------------------------------|
| **Associations with clinically significant weight loss ≥5%** | **Associations with acute radiation-induced esophagitis** |
| • Concurrent chemotherapy | • Mean esophageal dose |
| • Disease stage III or more | • Volume of the esophagus receiving 20, 30, 40, 50, and 60 Gy |
| • Maximum radiotherapy dose to the esophagus | |
| • Absolute esophageal length receiving doses of 40, 50, and 60 Gy | |
Patient centered outcomes

Studies in mixed tumor groups which included lung cancer patients have demonstrated the impact of weight loss on QoL, finding significantly worse QoL in patients with weight loss.36,37 In 104 lung, breast, and ovarian cancer patients, Ovesen et al, found QoL prior to any treatment was rated worse in patients who had experienced more than 5% loss of weight over the previous 3 months ($P<0.05$).37 In a mixed group of 907 cancer patients Nourissat et al, found similar results by comparing patients with and without 10% loss of weight since the onset of their illness, and at varying stages of treatment. The authors found mean global QoL was significantly poorer ($P<0.001$) in patients with weight loss.38

A number of studies investigating QoL have also looked at associations between weight loss or malnutrition and functional capacity using the functional sub-scales of the QoL questionnaires. The only one that included a large number of lung cancer patients (n=138) was the study by Nourissat et al.36 In this study, patients with greater than 10% weight loss had worse outcomes on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-C30) functional scales; physical functions ($P<0.001$); functional handicap ($P<0.001$); emotional functions ($P=0.004$); cognitive functions ($P<0.001$), and social functions ($P<0.001$). Similar results have been observed in studies of head and neck cancer, gastrointestinal cancer, and mixed cancer populations.36–41

Patients with poor nutritional status may be more likely to develop treatment toxicities which can result in a reduced dose of treatment being delivered.42,43 The development of treatment toxicities in patients with and without malnutrition or weight loss has also been studied using the symptom scales within QoL questionnaires. In addition, some studies have used toxicity scoring tools to determine differences. The results of studies investigating the impact of weight loss or malnutrition on treatment toxicities are less consistent than those for QoL and functional capacity. This may be due to the large range of toxicities that are assessed and the different methods used to assess them. Four such studies have been conducted in patients with lung cancer. Ross et al, assessed toxicity using the World Health Organization toxicity criteria in lung cancer patients undergoing chemotherapy treatment with and without 10% weight loss.44 NSCLC patients with weight loss were significantly more likely to develop severe anemia ($P=0.003$) but this finding was not observed in SCLC or patients with mesothelioma. No differences were observed for any other toxicities. In a study of NSCLC patients undergoing chemotherapy, treatment toxicities were assessed using the National Cancer Institute Common Toxicity Criteria for Adverse Events.45 When all toxicities were assessed, patients who were malnourished developed more toxicities than well-nourished patients (31 vs 22, $P=0.02$). In the study by Nourissat et al, described previously, all symptoms except insomnia in the EORTC-C30 symptom scale were significantly worse for patients with greater than 10% weight loss.36 A retrospective study of 425 stage IIIB NSCLC patients receiving chemoradiotherapy found that patients who lost weight during treatment experienced significantly more grade 3 hematological and non-hematological toxicities, including acute radiation-induced esophagitis, than patients who maintained or gained weight. In addition, the onset of acute radiation-induced esophagitis was significantly earlier (day 16 vs day 23 of radiotherapy, $P=0.02$) in weight losing patients.46

Numerous studies using the EORTC-C30 as a measure of QoL include a separate analysis of the fatigue symptom scale from this questionnaire. The results of these studies overwhelmingly support an association between fatigue and weight loss or malnutrition. Six of these studies, in head and neck or mixed cancer groups, report significantly worse fatigue in patients with weight loss36,38,39,41,46 or malnutrition.40 In the study by Nourissat et al, mean fatigue score in patients with less than 10% weight loss was 36.6 compared to 55.4 in patients with greater than 10% weight loss ($P<0.001$).

The use of health care resources is an important outcome measure in the setting of rising health care costs and an aging population. Studies in cancer patients including health care utilization as an outcome measure have usually focused on hospital admissions and length of stay. There is strong evidence that malnutrition affects health care utilization and costs. Only one study has investigated health care utilization specifically in lung cancer patients. The retrospective study by Topkan et al, of 425 stage IIIB NSCLC patients demonstrated a higher rate of hospitalization (11.3% vs 6.4%, $P=0.01$) in patients who lost weight during chemoradiotherapy compared to those who maintained or gained weight.46

Treatment outcomes

A number of studies across multiple cancer types have found associations between weight loss or malnutrition and poorer treatment outcomes. These associations were independent of disease stage and other known prognostic factors.34,44,48,49 The mechanism by which this might occur is not fully understood but it is suggested that patients with weight loss or malnutrition may have a poorer immune response, and poorer lung and cardiac function.42,44
A number of studies have shown a reduced ability to complete cancer treatment among malnourished patients. A retrospective cohort of lung cancer patients (n=780) undergoing chemotherapy treatment found less patients who had presented with weight loss completed three cycles of chemotherapy than those who presented without weight loss (67% vs 81%, P<0.001).44 When patients with NSCLC, SCLC, and mesothelioma were examined separately, this finding was confirmed in NSCLC patients (64% vs 78%, P=0.003) but not SCLC patients (77% vs 84%, P=0.1) or mesothelioma patients (53% vs 72%, P=0.05). When the authors looked at frequency of dose reductions or treatment delays between patients with and without weight loss no significant difference was found overall. However, more patients with weight loss experienced treatment delays in the sub-group with NSCLC (9% vs 4%, P=0.04). Similarly, in a study by Topkan et al, patients who lost weight were less able to tolerate full concurrent chemoradiotherapy treatment. While both weight losing and weight stable patients all completed the prescribed radiotherapy dose, more patients who lost weight required a chemotherapy dose reduction (23% vs 11%, P=0.02) or cessation of the chemotherapy component of treatment (17% vs 6.9%, P=0.007).46 Studies in other patient groups show similar findings.50,51

In a study of lung cancer patients undergoing chemotherapy, Ross et al, assessed both objective response to treatment on computed tomography scan and symptomatic response to treatment defined as improvement in a symptom maintained for a minimum of 3 weeks.44 No significant difference was found between patients with and without weight loss in objective response to treatment for either NSCLC or SCLC, however, a trend toward a lower response rate was observed in mesothelioma patients with weight loss (P=0.05). In contrast, NSCLC and mesothelioma patients with weight loss had fewer symptomatic responses compared to those without weight loss (44% vs 60%, P=0.004; 33% vs 65%, P=0.03, respectively). However, there was no difference in symptomatic response in SCLC (52% vs 64%, P=0.06). Again, studies in other patient groups demonstrate similar findings.52,49

A landmark study by Dewys et al, established the prognostic effect of weight loss, independent of performance status or extent of the tumor, in cancer patients undergoing 12 different chemotherapy protocols.41 This was a large study of multiple tumor groups (n=3,047), which demonstrated across all 12 protocols that patients with weight loss had reduced survival with this difference being significant in nine of the 12 protocols. In the protocols treating SCLC and NSCLC, median survival was shorter in patients with weight loss compared to those without weight loss (27 vs 34 weeks, P<0.05; 14 vs 20 weeks, P<0.01, respectively). In addition there appeared to be a difference in median survival by degree of weight loss in the NSCLC protocol (17 weeks 0%–5%; 13 weeks 5%–10%; 11 weeks 0%–10%, P<0.01). Ross et al, also determined weight loss to be an independent predictor of shorter overall survival in NSCLC (relative risk [RR] = 1.33, P=0.009), SCLC (RR = 1.5, P=0.003), and mesothelioma (RR = 1.92, P=0.03) patients undergoing chemotherapy treatment.44 These results are further supported by a study in stage III lung cancer patients undergoing chemoradiotherapy followed by surgery.53 Patients who experienced greater than 5% weight loss during chemoradiotherapy had a shorter overall survival (hazard ratio [HR] 2.80, P=0.03). In the same study, patients who had a body mass index greater than 25 prior to treatment but lost greater than 5% weight during chemoradiation, had a shorter overall and progression-free survival (HR 4.63, P=0.005; HR 6.03, P=0.007, respectively). Also in radiotherapy patients, Topkan et al, found better overall survival, progression-free survival, and distant metastasis free survival (all P<0.05) in stage IIIB NSCLC patients who maintained or gained weight during chemoradiotherapy compared to those who lost weight.46 In surgical lung cancer patients, impaired nutritional status appears to be associated with reduced long-term survival but not mortality in hospital following surgery. Studies have reported an independent association between nutritional impairment measured by body mass index, fat free mass index or weight loss and reduced long-term survival,53,54 but failed to find an association between nutritional parameters and 30-day in-hospital mortality in surgical lung cancer patients.55

With a high prevalence of malnutrition among lung cancer patients and in the setting of strong evidence demonstrating poorer outcomes for malnourished patients, it is important to examine the most effective type of nutrition intervention to prevent or treat malnutrition in this population.

Nutrition interventions

Early research conducted during the 1980s on nutrition intervention in lung cancer focused on the effect of parenteral nutrition during chemotherapy and radiotherapy on treatment outcomes and survival with mixed results.56–59 Several of these randomized controlled trials were underpowered to detect an effect.59 It is now standard clinical practice to reserve the use of parenteral nutrition for those patients with a non-functioning gastrointestinal tract.60 and therefore the results of these studies are now of limited interest.
More recent studies have focused on the effect of novel agents, such as omega-3 fatty acids, or dietary counseling in lung cancer patients.

Dietary counseling
Intensive, individualized dietary counseling or medical nutrition therapy is the intervention which has been demonstrated to improve dietary intake, nutritional status, functional status, and QoL in head and neck and gastrointestinal cancer patients treated with radiotherapy.16,35,61 However, there have been limited high quality studies undertaken investigating this intervention in patients with lung cancer. A recent systematic review on nutrition interventions in lung cancer patients treated with radiotherapy and/or chemotherapy revealed only five studies have investigated either dietary counseling or oral supplements in this patient group over the past 30 years.62 The systematic review found that simple dietary counseling improved energy and protein intake in lung cancer patients receiving chemotherapy but appeared to have no impact on other outcomes including weight, nutritional status, QoL, treatment response or survival. However, the studies in chemotherapy patients all had substantial limitations which may have precluded the ability to detect an impact on these outcomes. There was insufficient evidence found investigating dietary counseling or oral supplements in lung cancer patients receiving radiotherapy and therefore no conclusion could be drawn on the impact of this intervention. Of note, none of the studies had investigated intensive, individualized dietary counseling. It has previously been reported that undertaking supportive care research in lung cancer patients poses challenges including low recruitment and high attrition which may explain the paucity of studies in this area.63 A recent pilot randomized trial has established the feasibility of investigating intensive, individualized dietary counseling in lung cancer patients receiving radiotherapy paving the way for future larger trials to determine the efficacy of this intervention in lung cancer patients. The pilot randomized trial demonstrated clinically important differences favoring the intervention for weight, fat-free mass, physical wellbeing, and functional wellbeing, however, these results require confirmation in a larger sample.64 There remains limited evidence regarding the efficacy of dietary counseling in lung cancer patients, however recent studies show promise and scope for further well-designed research in this area.

Omega-3 fatty acids
Patients with advanced lung cancer are reported to have a relatively high prevalence of cancer cachexia which is generally believed to be resistant to traditional forms of nutrition intervention such as dietary counseling.65,66 Therefore, nutrition intervention research in lung cancer patients has tended to focus on the use of novel agents such as omega-3 fatty acids as a treatment for cancer cachexia.67-69 A 2013 systematic review of the effect of omega-3 fatty acids on clinical outcomes in patients with cancer found mixed results.70 The review showed omega-3 fatty acids to be a safe intervention with a positive effect on QoL and physical activity. However, the effect of omega-3 fatty acids on weight, fat-free mass, and performance status was deemed inconclusive, while no benefit for nutritional intake, appetite or survival were found. There have been several studies investigating omega-3 fatty acids in lung cancer patients. In a large double blind randomized trial of 518 advanced lung and gastrointestinal cancer patients not receiving any anti-cancer treatment, no benefit on weight, fat-free mass, physical function, appetite or survival were found from supplementation with 2 g or 4 g doses of eicosapentaenoic acid.71 Two smaller studies in lung cancer patients receiving active treatment have shown more positive results. In 40 lung cancer patients receiving first line chemotherapy treatment, Murphy et al, found those who were randomized to receive 2.2 g of fish oil maintained overall weight and maintained or gained muscle mass, measured from computed tomography images, over the course of chemotherapy compared to those who received standard care.68 However, it should be noted the authors acknowledge the limitations of the open-label study design and the possibility the improvement in weight may have been in part due to the chemotherapy treatment itself. Another study in 40 stage III NSCLC patients receiving chemoradiation treatment showed that patients randomized to receive 2.9 g fish oil within an oral nutrition supplement had better weight and fat-free mass maintenance and improved protein and energy intake than those who received an isocaloric control supplement.69 While there does appear to be some benefit to omega-3 fatty acid supplementation for lung cancer patients on treatment, larger studies are required to confirm these findings.

Enteral nutrition
While there are no studies reporting specifically on the efficacy of enteral nutrition in lung cancer patients, some studies have used enteral nutrition as a component of nutrition intervention with fish oil or dietary counseling, however the use of enteral nutrition in these studies was in a limited capacity.69,72 Enteral nutrition is used relatively infrequently in patients with lung cancer, with reports of as few as 12% of
patients commencing enteral nutrition. In clinical practice, enteral nutrition is more likely to be provided to lung cancer patients treated with curative intent chemoradiation where esophagitis can manifest as an acute toxicity severely limiting oral intake. Emerging knowledge of the factors placing lung cancer patients at higher risk of clinically significant weight loss may provide the impetus required to utilize enteral nutrition more frequently in lung cancer patients. Studies evaluating the efficacy of using enteral nutrition as a component of medical nutrition therapy in higher nutritional risk lung cancer patients are required.

Multidisciplinary

Systematic reviews indicate exercise interventions are associated with improved exercise capacity, physical strength, functional performance, and some domains of QoL in patients with NSCLC. Early studies indicate that cancer prehabilitation programs, mostly with exercise interventions prior to treatment, may improve treatment tolerance and the ability to undergo curative intent treatment. Models of care involving multi-modal nutritional rehabilitation programs, including nutritional, physical, and physiological interventions following completion of cancer treatment, have demonstrated positive effects on physical activity levels, fatigue, symptoms, weight, and nutritional status. While no studies of multi-modal nutrition and exercise interventions have been completed specifically in lung cancer patients, there have been a number of reports of successful outcomes from cancer nutrition rehabilitation programs accessed by patients from a broad range of tumor groups. An uncontrolled prospective intervention study of 188 advanced cancer patients who attended a 10- to 12-week interdisciplinary program which provided nutritional counseling alongside an exercise program and dedicated symptom control demonstrated strong improvements in physical activity and fatigue, moderate improvements in 6-minute walk test, while 77% of patients maintained their weight. Within this program patients had access to a dietitian, physical therapist, occupational therapist, physician, social worker, and clinical nurse specialist. A further study of 173 cancer patients attending a similar 8-week interdisciplinary program, including access to the same health professionals, reports significant improvements in physical performance, nutrition, symptom severity, fatigue, and physical endurance. In light of the multidisciplinary nature of the clinical management of cancer patients, further high quality research is required to investigate the efficacy of multi-modal interventions involving nutritional, physical and psychological interventions.

Conclusion

Lung cancer patients experience a high symptom burden with many of these symptoms affecting nutritional intake and the development of malnutrition, with the potential to subsequently impact patient-related and treatment outcomes. Nutrition support and interventions are vital to optimize the wellbeing of lung cancer patients and maximize their ability to complete lengthy cancer treatments. Current research on nutrition interventions in lung cancer patients shows promise in a number of areas including intensive individualized dietary counseling, fish oil supplementation as well as multi-modal interventions encompassing both nutrition and exercise. Further good quality research and large clinical trials are needed to establish effective interventions in this patient group.

Disclosure

The author reports no conflicts of interest in this work.

References


